Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
alliance, ASC, ASUNo, begun, BELONG, beta, book, brand, broad, category, clarification, close, commonly, creditworthy, de, deconsolidate, depletion, distinguish, dosing, EITF, EPS, escalation, estate, expressing, Fc, fifteen, FILM, foot, free, FUMADERMtm, fusion, galiximab, heading, imbalance, immunomodulation, investee, IssueNo, judge, lifetime, LN, location, LUCID, lumiliximab, MAb, member, modified, objective, occupancy, orEITF, outpatient, Overview, path, pharmacokinetic, prematurely, PRIMA, protein, real, recharacterizing, RecognitionTopic, recombinant, rehearing, retire, retired, revealing, reversed, rFIXFc, sBLA, SecuritiesTopic, short, slightly, square, step, stop, stopped, strong, survival, TaxTopic, technique, theConsolidation, theConsolidationTopic, theIncome, theInvestment, therapy, theRevenue, tolerated, undelivered, UnderEITF, unrelated, UpdateNo, Weston, withinEITF, writ, XIII
Filing tables
Filing exhibits
Related press release
BIIB similar filings
Filing view
External links